Celiprolol - Acer Therapeutics

Drug Profile

Celiprolol - Acer Therapeutics

Alternative Names: ACER-002; EDSIVO; VASEBRA™

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acer Therapeutics
  • Class Antihypertensives; Heart failure therapies; Ischaemic heart disorder therapies; Phenylurea compounds; Propanolamines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ehlers-Danlos syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ehlers-Danlos syndrome

Most Recent Events

  • 16 Oct 2017 Chemical structure information added
  • 20 Dec 2016 Acer Therapeutics plans to file an NDA for Ehlers-Danlos syndrome with the US FDA in the first half of 2018
  • 13 Dec 2016 Acer Therapeutics obtains exclusive rights to use celiprolol pivotal clinical data from the Greater Paris University Hospitals AP-HP
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top